September 29, 2014Open Access

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

Key Points

Key points are not available for this paper at this time.

Abstract

A combination of dabrafenib and trametinib, as compared with dabrafenib alone, improved the rate of progression-free survival in previously untreated patients who had metastatic melanoma with BRAF V600E or V600K mutations. (Funded by GlaxoSmithKline; Clinical Trials.gov number, NCT01584648.).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Long et al. (Mon,) studied this question.

www.synapsesocial.com/papers/699ec393713733805dde645a — DOI: https://doi.org/10.1056/nejmoa1406037

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib· 2012 · 2,145 citations
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial· 2012 · 933 citations
Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma· 2013 · 425 citations
BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact

Authors

Georgina V. Long

Daniil Stroyakovskiy

Helen Gogas

Journals

New England Journal of Medicine

Actions

Institutions

Apple (Israel)

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion